AUPH

Aurinia Pharmaceuticals Stock Analysis

AI Rating

Great
  • Quality9/10
  • Growth↑ 9/10
  • Momentum↑ 7/10
Aurinia Pharmaceuticals sales and earnings growth
AUPH Growth
Great
  • Revenue Y/Y↑ 20.62%
  • EPS Y/Y↑ 514.29%
  • FCF Y/Y↑ 323.53%
Aurinia Pharmaceuticals gross and profit margin trends
AUPH Profitability
Good
  • Gross margin ↑ 88.90%
  • EPS margin↑ 29.30%
  • ROIC↑ 18.80%
Aurinia Pharmaceuticals net debt vs free cash flow
AUPH Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 19.0

Aurinia Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗